In this issue of Blood, , Gulla et al identify GABA type A receptor-associated protein, GABARAP, as a key player in mediating resistance to immunogenic chemotherapy in multiple myeloma (MM), by halting calreticulin translocation to the external leaflet fl et of the cell membrane. By shedding light on immunogenic cell death (ICD), the authors provide a framework for potential novel combination treatments including ICD inducers to restore anti-MM immunity.(1)
Immunogenic therapy: new actors in myeloma
Solimando, Antonio G.;Vacca, Angelo
2024-01-01
Abstract
In this issue of Blood, , Gulla et al identify GABA type A receptor-associated protein, GABARAP, as a key player in mediating resistance to immunogenic chemotherapy in multiple myeloma (MM), by halting calreticulin translocation to the external leaflet fl et of the cell membrane. By shedding light on immunogenic cell death (ICD), the authors provide a framework for potential novel combination treatments including ICD inducers to restore anti-MM immunity.(1)File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
blood_bld-2024-024709-c-main.pdf
non disponibili
Descrizione: articolo principale
Tipologia:
Documento in Versione Editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
423.97 kB
Formato
Adobe PDF
|
423.97 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
